These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

251 related items for PubMed ID: 22253738

  • 41. In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates.
    Saravolatz L, Pawlak J, Johnson L.
    Antimicrob Agents Chemother; 2010 Jul; 54(7):3027-30. PubMed ID: 20404122
    [Abstract] [Full Text] [Related]

  • 42. Evaluation of vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus and heterogeneously vancomycin-intermediate S. aureus in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations.
    Leonard SN, Rybak MJ.
    J Antimicrob Chemother; 2009 Jan; 63(1):155-60. PubMed ID: 18984644
    [Abstract] [Full Text] [Related]

  • 43. walK and clpP mutations confer reduced vancomycin susceptibility in Staphylococcus aureus.
    Shoji M, Cui L, Iizuka R, Komoto A, Neoh HM, Watanabe Y, Hishinuma T, Hiramatsu K.
    Antimicrob Agents Chemother; 2011 Aug; 55(8):3870-81. PubMed ID: 21628539
    [Abstract] [Full Text] [Related]

  • 44. Contribution of selected gene mutations to resistance in clinical isolates of vancomycin-intermediate Staphylococcus aureus.
    Hafer C, Lin Y, Kornblum J, Lowy FD, Uhlemann AC.
    Antimicrob Agents Chemother; 2012 Nov; 56(11):5845-51. PubMed ID: 22948864
    [Abstract] [Full Text] [Related]

  • 45. An RpoB mutation confers dual heteroresistance to daptomycin and vancomycin in Staphylococcus aureus.
    Cui L, Isii T, Fukuda M, Ochiai T, Neoh HM, Camargo IL, Watanabe Y, Shoji M, Hishinuma T, Hiramatsu K.
    Antimicrob Agents Chemother; 2010 Dec; 54(12):5222-33. PubMed ID: 20837752
    [Abstract] [Full Text] [Related]

  • 46. Role of the msaABCR Operon in Cell Wall Biosynthesis, Autolysis, Integrity, and Antibiotic Resistance in Staphylococcus aureus.
    G C B, Sahukhal GS, Elasri MO.
    Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31307991
    [Abstract] [Full Text] [Related]

  • 47. Vancomycin tolerance in methicillin-resistant Staphylococcus aureus: influence of vancomycin, daptomycin, and telavancin on differential resistance gene expression.
    Rose WE, Fallon M, Moran JJ, Vanderloo JP.
    Antimicrob Agents Chemother; 2012 Aug; 56(8):4422-7. PubMed ID: 22687502
    [Abstract] [Full Text] [Related]

  • 48. Adaptive Laboratory Evolution of Staphylococcus aureus Resistance to Vancomycin and Daptomycin: Mutation Patterns and Cross-Resistance.
    Gostev V, Kalinogorskaya O, Sopova J, Sulian O, Chulkova P, Velizhanina M, Tsvetkova I, Ageevets I, Ageevets V, Sidorenko S.
    Antibiotics (Basel); 2023 May 18; 12(5):. PubMed ID: 37237831
    [Abstract] [Full Text] [Related]

  • 49. Telavancin demonstrates activity against methicillin-resistant Staphylococcus aureus isolates with reduced susceptibility to vancomycin, daptomycin, and linezolid in broth microdilution MIC and one-compartment pharmacokinetic/pharmacodynamic models.
    Smith JR, Barber KE, Hallesy J, Raut A, Rybak MJ.
    Antimicrob Agents Chemother; 2015 Sep 18; 59(9):5529-34. PubMed ID: 26124162
    [Abstract] [Full Text] [Related]

  • 50. Increasing Trend of Heterogeneous Vancomycin Intermediate Staphylococcus aureus in a Tertiary Care Center of Northern India.
    Singh A, Prasad KN, Misra R, Rahman M, Singh SK, Rai RP, Tripathi A, Srivastava JK.
    Microb Drug Resist; 2015 Oct 18; 21(5):545-50. PubMed ID: 26430942
    [Abstract] [Full Text] [Related]

  • 51. Relevance of vancomycin-intermediate susceptibility and heteroresistance in methicillin-resistant Staphylococcus aureus bacteraemia.
    Khatib R, Jose J, Musta A, Sharma M, Fakih MG, Johnson LB, Riederer K, Shemes S.
    J Antimicrob Chemother; 2011 Jul 18; 66(7):1594-9. PubMed ID: 21525024
    [Abstract] [Full Text] [Related]

  • 52. Studies on the mechanism of telavancin decreased susceptibility in a laboratory-derived mutant.
    Song Y, Lunde CS, Benton BM, Wilkinson BJ.
    Microb Drug Resist; 2013 Aug 18; 19(4):247-55. PubMed ID: 23551248
    [Abstract] [Full Text] [Related]

  • 53. Evaluation of the Presence and Characterization of Vancomycin-Intermediate and Heterogeneous Vancomycin-Intermediate Level Resistance Among Bloodstream Isolates of Methicillin-Resistant Staphylococcus aureus.
    Ozmen Capin BB, Tekeli A, Karahan ZC.
    Microb Drug Resist; 2020 Mar 18; 26(3):238-244. PubMed ID: 31545160
    [Abstract] [Full Text] [Related]

  • 54. Phenotypic Characteristics of Vancomycin-Non-Susceptible Staphylococcus aureus.
    Sirichoat A, Wongthong S, Kanyota R, Tavichakorntrakool R, Chanawong A, Welbat JU, Lulitanond A.
    Jundishapur J Microbiol; 2016 Jan 18; 9(1):e26069. PubMed ID: 27099678
    [Abstract] [Full Text] [Related]

  • 55. Generation of a vancomycin-intermediate Staphylococcus aureus (VISA) strain by two amino acid exchanges in VraS.
    Berscheid A, François P, Strittmatter A, Gottschalk G, Schrenzel J, Sass P, Bierbaum G.
    J Antimicrob Chemother; 2014 Dec 18; 69(12):3190-8. PubMed ID: 25103491
    [Abstract] [Full Text] [Related]

  • 56. Vancomycin and daptomycin minimum inhibitory concentration distribution and occurrence of heteroresistance among methicillin-resistant Staphylococcus aureus blood isolates in Turkey.
    Sancak B, Yagci S, Gür D, Gülay Z, Ogunc D, Söyletir G, Yalcin AN, Dündar DO, Topçu AW, Aksit F, Usluer G, Ozakin C, Akalin H, Hayran M, Korten V.
    BMC Infect Dis; 2013 Dec 10; 13():583. PubMed ID: 24325260
    [Abstract] [Full Text] [Related]

  • 57. Characterization of a daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus strain in a patient with endocarditis.
    Julian K, Kosowska-Shick K, Whitener C, Roos M, Labischinski H, Rubio A, Parent L, Ednie L, Koeth L, Bogdanovich T, Appelbaum PC.
    Antimicrob Agents Chemother; 2007 Sep 10; 51(9):3445-8. PubMed ID: 17620372
    [Abstract] [Full Text] [Related]

  • 58. Defective pgsA contributes to increased membrane fluidity and cell wall thickening in Staphylococcus aureus with high-level daptomycin resistance.
    Freeman CD, Hansen T, Urbauer R, Wilkinson BJ, Singh VK, Hines KM.
    mSphere; 2024 Jun 25; 9(6):e0011524. PubMed ID: 38752757
    [Abstract] [Full Text] [Related]

  • 59. Impact of vancomycin use trend change due to the availability of alternative antibiotics on the prevalence of Staphylococcus aureus with reduced vancomycin susceptibility: a 14-year retrospective study.
    Kang YR, Kim SH, Chung DR, Ko JH, Huh K, Cho SY, Kang CI, Peck KR.
    Antimicrob Resist Infect Control; 2022 Aug 05; 11(1):101. PubMed ID: 35932086
    [Abstract] [Full Text] [Related]

  • 60. Resistance or decreased susceptibility to glycopeptides, daptomycin, and linezolid in methicillin-resistant Staphylococcus aureus.
    Nannini E, Murray BE, Arias CA.
    Curr Opin Pharmacol; 2010 Oct 05; 10(5):516-21. PubMed ID: 20598637
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.